We also show that a serum CEA level of less than 10 ng/ml was a predictor of favorable outcomes in advanced lung adenocarcinoma patients with EGFR-sensitive mutations (exon 19 deletion and L858R). The gene discussed is EGFR; the disease is lung adenocarcinoma.